InnoCare Pharma Executive and Leadership Team

Nghia Ba, the Chief Executive Officer at InnoCare Pharma, directs the company's overarching strategy and vision. This leadership role involves guiding the organization's efforts to develop innovative drugs targeting malignant tumors and autoimmune diseases, aligning with the mission to address significant unmet clinical needs. The Chief Executive Officer ensures that the company's comprehensive research and commercialization capabilities are leveraged to create first-in-class or best-in-class therapies for global markets. Nghia Ba oversees the strategic direction of the pipeline in hematological malignancies, autoimmune diseases, and solid tumors, driving the commitment to deliver high-quality innovative medicines. This executive's focus is on fostering a culture of scientific-driven innovation, ensuring InnoCare Pharma remains at the forefront of pharmaceutical development and patient benefit worldwide. Nghia Ba's leadership ensures the company's strategic objectives translate into tangible advancements in patient care.

Xin Fu, the Chief Financial Officer at InnoCare Pharma, manages all financial operations and strategic financial planning. This role is critical in supporting the company's mission to develop innovative drugs for oncology and autoimmune diseases by ensuring robust financial health and resource allocation. The Chief Financial Officer oversees budgeting, forecasting, and financial reporting, providing essential insights for strategic decision-making. Xin Fu's responsibilities include managing capital structure, investor relations, and securing funding to advance the company's pipeline of first-in-class or best-in-class therapies for global markets. By maintaining fiscal discipline and identifying financial opportunities, the Chief Financial Officer directly contributes to the company's ability to deliver high-quality innovative medicines worldwide. Xin Fu's financial acumen is vital for sustaining the company's growth and its commitment to addressing unmet clinical needs.

Kevin Gao, the Chief Operations Officer at InnoCare Pharma, directs the operational execution of the company's drug development and commercialization strategies. This leadership position is fundamental to translating the company's focus on innovative therapies for malignant tumors and autoimmune diseases into tangible patient benefits. The Chief Operations Officer oversees the integration of research, development, manufacturing, and supply chain functions, ensuring efficiency and quality across all operational facets. Kevin Gao's responsibilities include optimizing processes to support the creation of first-in-class or best-in-class therapies for global markets, ensuring seamless delivery of high-quality innovative medicines. By managing day-to-day operations and driving operational excellence, the Chief Operations Officer plays a key part in the company's commitment to addressing significant unmet clinical needs. Kevin Gao's operational oversight is crucial for the successful implementation of InnoCare Pharma's strategic goals.

Shawn Zhang, the Chief Medical Officer at InnoCare Pharma, leads the clinical development and medical affairs strategy for the company's innovative drug pipeline. This role is central to the company's mission of developing therapies for malignant tumors and autoimmune diseases, ensuring clinical efficacy and patient safety are paramount. The Chief Medical Officer oversees the design and execution of clinical trials, guiding the progression of first-in-class or best-in-class therapies toward global market approval. Shawn Zhang's expertise is critical in translating scientific discoveries into effective treatments, driving the commitment to deliver high-quality innovative medicines that address significant unmet clinical needs. By providing medical leadership and strategic direction for clinical programs, the Chief Medical Officer ensures InnoCare Pharma's research directly benefits patients worldwide. Shawn Zhang's medical insights are indispensable for the company's success in pharmaceutical innovation.